Last reviewed · How we verify
Placebo to Ertugliflozin
Ertugliflozin works by inhibiting the SGLT2 protein in the kidneys, reducing glucose reabsorption and lowering blood glucose levels.
Ertugliflozin works by inhibiting the SGLT2 protein in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. Used for Treatment of type 2 diabetes, Reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
At a glance
| Generic name | Placebo to Ertugliflozin |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
This action leads to a decrease in glucose levels in the blood, which can help manage type 2 diabetes. By reducing glucose reabsorption, the kidneys excrete more glucose in the urine, further lowering blood glucose levels.
Approved indications
- Treatment of type 2 diabetes
- Reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease
Common side effects
- Ketoacidosis
- Increased urination
- Dehydration
- Nausea
- Vomiting
- Hypotension
- Increased risk of amputations
- Increased risk of fractures
- Increased risk of urinary tract infections
- Increased risk of genital mycotic infections
Key clinical trials
- Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059) (PHASE3)
- Ertugliflozin in Chronic Heart Failure (PHASE2)
- Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study (PHASE3)
- Ertugliflozin for Functional Mitral Regurgitation (PHASE3)
- Effect of Ertugliflozin on Cardiac Function in Diabetes (PHASE3)
- ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy (PHASE4)
- ERTU-SODIUM: Study on the Effects of Ertugliflozin on Sodium Storage, Interstitial Volume, and Plasma Volume in HFrEF (PHASE4)
- Renal Oxygenation, Oxygen Consumption and Hemodynamic Kinetics in Type 2 DIabetes: an Ertugliflozin Study. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to Ertugliflozin CI brief — competitive landscape report
- Placebo to Ertugliflozin updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI